Abbott Laboratories (ABT)

Basic

  • Market Cap

    $205.83B

  • EV

    $214.65B

  • Shares Out

    1,735.18M

  • Revenue

    $40.11B

  • Employees

    114,000

Margins

  • Gross

    55.32%

  • EBITDA

    26.09%

  • Operating

    18%

  • Pre-Tax

    16.61%

  • Net

    14.27%

  • FCF

    12.61%

Returns (5Yr Avg)

  • ROA

    6.16%

  • ROTA

    27.64%

  • ROE

    16.1%

  • ROCE

    11.96%

  • ROIC

    11.34%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $124.92

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $7,279M

  • Net Debt

    $8,594M

  • Debt/Equity

    0.41

  • EBIT/Interest

    11.33

Growth (CAGR)

  • Rev 3Yr

    5.04%

  • Rev 5Yr

    5.58%

  • Rev 10Yr

    7.39%

  • Dil EPS 3Yr

    9.4%

  • Dil EPS 5Yr

    20%

  • Dil EPS 10Yr

    9.97%

  • Rev Fwd 2Yr

    5.83%

  • EBITDA Fwd 2Yr

    7.38%

  • EPS Fwd 2Yr

    7.53%

  • EPS LT Growth Est

    8%

Dividends

  • Yield

  • Payout

    63.48%

  • DPS

    $2.08

  • DPS Growth 3Yr

    10.78%

  • DPS Growth 5Yr

    12.39%

  • DPS Growth 10Yr

    12.51%

  • DPS Growth Fwd 2Yr

    5.98%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

Total Revenues

31,904

34,608

43,075

43,653

40,109

Total Revenues % Chg.

4.3%

8.5%

24.5%

1.3%

-8.1%

Cost of Goods Sold, Total

13,231

15,003

18,080

19,083

17,919

Gross Profit

18,673

19,605

24,995

24,570

22,190

Selling General & Admin Expenses, Total

9,540

9,591

11,006

10,703

10,385

R&D Expenses

2,440

2,420

2,738

2,741

2,619

Amortization of Goodwill and Intangible Assets

1,936

2,132

2,047

2,013

1,966

Other Operating Expenses, Total

13,916

14,143

15,791

15,457

14,970

Operating Income

4,757

5,462

9,204

9,113

7,220

Interest Expense, Total

-670

-546

-533

-558

-637

Interest And Investment Income

94

46

43

183

385

Net Interest Expenses

-576

-500

-490

-375

-252

Currency Exchange Gains (Loss)

-7

8

-1

-2

-41

Other Non Operating Income (Expenses)

-34

13

7

-40

-22

EBT, Excl. Unusual Items

4,140

4,983

8,720

8,696

6,905

Restructuring Charges

-509

-234

-144

Merger & Related Restructuring Charges

Gain (Loss) On Sale Of Investments

-115

-45

-39

Gain (Loss) On Sale Of Assets

Asset Writedown

-111

-100

Legal Settlements

100

Other Unusual Items

-63

42

EBT, Incl. Unusual Items

4,077

4,968

8,211

8,306

6,664

Income Tax Expense

390

497

1,140

1,373

941

Earnings From Continuing Operations

3,687

4,471

7,071

6,933

5,723

Earnings Of Discontinued Operations

24

Net Income

3,687

4,495

7,071

6,933

5,723

Preferred Dividend and Other Adjustments

21

22

29

28

22

Net Income to Common Incl Extra Items

3,666

4,473

7,042

6,905

5,701

Net Income to Common Excl. Extra Items

3,666

4,449

7,042

6,905

5,701

Total Shares Outstanding

1,762.5

1,771.2

1,764.1

1,737.8

1,734.1

Weighted Avg. Shares Outstanding

1,768

1,773

1,775

1,753

1,740

Weighted Avg. Shares Outstanding Dil

1,781

1,786

1,789

1,764

1,749

EPS

2.1

2.5

4

3.9

3.3

EPS Diluted

2.1

2.5

3.9

3.9

3.3

EBITDA

7,771

8,789

12,742

12,380

10,463